Tigermed (3347.HK) opened high in the dark market on August 6, closing up 18.2% at HK $118.2, with a turnover of HK $186 million, with the latest total market value of HK $101.24 billion. The company is a leading integrated biopharmaceutical R & D service provider in China, with a net tangible asset value of HK $14.56-16.01 per share. The global offering of about 107 million H shares, the Hong Kong public offering was 414.39 times subscribed. Guosheng Securities refers to the company is the domestic clinical CRO leader, H-share listing after the growth is expected to accelerate, firmly optimistic about the development of the company, the first to "buy" rating.
泰格医药(3347.HK)暗盘大涨逾18% 市值超千亿港元
Tigermed (3347.HK) rose more than 18% in the dark market, with a market capitalization of more than HK $100 billion.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.